Bladder cancer

Current Opinion in Oncology

Volumn 9, Issue 3, 1997, Pages 295-300

  Özen, Haluk ^a  

^a Gazi Osman Pa a   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CISPLATIN; DOXORUBICIN; METHOTREXATE; MITOMYCIN C; VINBLASTINE;

BLADDER CANCER; BLADDER RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER SCREENING; CANCER SURGERY; CLINICAL TRIAL; CYSTECTOMY; CYSTOSCOPY; HUMAN; INTRADERMAL DRUG ADMINISTRATION; INTRAVESICAL DRUG ADMINISTRATION; MOLECULAR GENETICS; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY;

EID: 0030878436     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199709030-00013     Document Type: Short Survey

References (19)

1. Soloway MS. Briggman JV, Carpinito GA, Chodak GW. Church PA. Lamm DL, Messing E, Pasciak RM. Reservitz GB, Rutstakis DB. Sarosdy MF, Stadler WM, Thiel RP, Hayden CL: Use of new tumor marker, urinary MNP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996, 156:363-367. Nuclear matrix protein 22 was found to be highly predictive of tumor status in subsequent cystoscopy results if the urine specimen was collected at least 5 days after the previous cystoscopy. NMP22 was 100% positive in patients who progressed to invasive disease. The frequency of cystoscopies in certain low-risk patients may be decreased according to the NMP22 level once this assay is fully established.
2. Mao I, Schoenberg MP, Scicchitano M, Erozan YS, Merio A. Schab D, Sidransky D: Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996, 271:659-662. Microsatellite DNA markers detected 95% of the tumors, whereas conventional cytology was successful in only 50%. Moreover, the authors claimed that the technique was inexpensive and does not need extensive expertise for interpretation.
3. Balbay D. Özen H, Ozkardes H, Barut A, Bakkaloglu M. Tasar C, Remzi D: Detection of urinary interleukin-2, interleukin-2 receptor and tumor necrosis factor levels in patients with superficial bladder tumors after intravesical BCG immunotherapy. Urology 1994. 43:187-190.
4. De Reijke TM, De Boer EC. Kurth KH, Schamhart DHJ: Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996, 155:477-482. The authors have shown that peak levels of urinary interleukin-2 correlated with tumor recurrence. It is not clear whether the finding that this correlation was valid for only 6 months will have clinical implications in regard to schedule of BCG administration.
5. Luftenegger W, Ackermann DK, Futterlieb A, Kraft R, Minder CE. Nadelhaft P. Studer UE: Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 1996, 155:483-487.
6. Tolley DA, Parmar MKB, Grigor KM, Lallemand G. for The Medical Research Council Superficial Bladder Cancer Working Party: The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow-up. J Urol 1996, 155:1233-1238.
7. Oesterlink W, Kurth KH, Schroder F, Bultinck J, Hammond B. Sylvester R, and members of the European Organization for Research and Treatment of Cancer Genitourinary Group: A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993, 749-752.
8. Bochner BH. Cote RJ, Weidner N, Groshen S, Chen S, Skinner DG. Nichols PW: Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1996, 87:1603-1612. Microvessel density in invasive bladder cancers have been shown to be strongly and independently associated with disease recurrence and overall survival rates. Furthermore, statistically significant correlation was also found in disease progression in localized disease between patients with low and high microvessel density. This finding may aid the clinician to identify patients who require adjuvant chemotherapy after cystectomy.
9. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of trombospondin-1. Science 1994, 265:1582-1584.
10. Schoenberg MP, Walsh PC, Breazeale DR, Marshall FF, Mostwin JL, Brendler CB: Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year follow-up. J Urol 1996, 155:490-494. The long-term local recurrence rates and disease-specific survival rates for patients with invasive bladder cancer who have undergone nerve sparing radical cystectomy have been shown to be at least as good as those of conventional cystectomy series. Potency was recovered in the majority of young patients without compromising the cure rate.
11. Stein JP, Cote RJ, Freeman JA, Esrig D, Elmajian DA, Groshen S, Skinner EC. Boyd SD. Lieskovsky G, Skinner DG: Indications for lower urinary tract reconstruction in women after cystectomy for bladder cancer: a pathological review of female cystectomy specimens. J Urol 1995, 154:1329-1333. The authors have retrospectively reported their experience in continent diversions performed in females. They recommend continent diversions in females unless the tumor did not infiltrate the bladder, neck, and anterior vaginal wall.
12. Hautman RE, Paiss T, Petriconi R: The ileal neobladder in women: 9 years of experience with 18 patients. J Urol 1996, 155:76-81.
13. Navon DN, Wong AK, Weinberg AC, Ahlering TE: A comparative study of postoperative complications associated with the modified Indiana pouch in elderly versus younger patients. J Urol 1995. 154:1325-1328.
14. Pannek J, Haupl G, Schulze H, Senge T: Influence of continent ileal urinary diversion on vitamin B12 absorption. J Urol 1996, 155:1206-1208.
15. Campanello M, Herlitz H, Lindstedt G, Mellstrom D, Wilske J, Akerlund S, Jonsson O: Bone mineral and related biochemical variables in patients with Kock ileal reservoir or Bricker conduit for urinary diversion. J Urol 1996, 155:1209-1213.
16. Freiha F, Reese J, Torti FM: A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996, 155:495-500.
17. Miller RS, Freiha FS, Reese JH, Ozen H, Torti FM: Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urethelium. J Urol 1993, 150:65-69.
18. Donat SM, Herr HW. Bajorin DF, Fair WR, Sogani PC, Russo P, Scheinfeld J, Scher HI: Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. J Urol 1996, 156:368-371.
19. Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, True L, Shipley W: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase 2 trial 8802, J Clin Oncol 1996, 14:119-126, The Radiation Therapy Oncology Group have reported their experience on a bladder preserving protocol consisting of a neoadjuvant chemotherapy and radiotherapy with concurrent cisplatin. It has been shown that bladder may be spared in 60% of patients with invasive bladder cancers without compromising overall survival. This therapy, however, requires meticulous follow-up and patient compliance and unless phase III comparative trials with cystectomy would be initiated the controversy about the best treatment will not be solved